N-Substituted Glutamyl Sulfonamides as Inhibitors of GCP2
17. Humblet V., Lapidus R., Williams L.R., Tsukamoto T., Rojas C.,
31. Supuran C.T., Innocenti A., Mastrolorenzo A., Scozzafava A.
(2004) Antiviral sulfonamide derivatives. Mini Rev Med
Chem;4:189–200.
Majer P., Hin B., Ohnishi S., De Grand A.M., Zaheer A., Renze
J.T., Nakayama A., Slusher B.S., Frangioni J.V. (2005) High-affi-
nity near-infrared fluorescent small-molecule contrast agents for
in vivo imaging of prostate-specific membrane antigen. Mol
Imaging;4:448–462.
32. Vitharana D., France J.E., Scarpetti D., Bonneville G.W., Majer P.,
Tsukamoto T. (2002) Synthesis and biological evaluation of (R)- and
(S)-2-(phosphonomethyl)pentanedioic acids as inhibitors of gluta-
mate carboxypeptidase II. Tetrahedron Asymmetry;13:1609–1614.
33. Wu L.Y., Anderson M.O., Toriyabe Y., Maung J., Campbell T.Y., Ta-
jon C., Kazak M., Moser J., Berkman C.E. (2007) The molecular
pruning of a phosphoramidate peptidomimetic inhibitor of pros-
tate-specific membrane antigen. Bioorg Med Chem;15:7434–7443.
34. Maung J., Mallari J.P., Girtsman T.A., Wu L.Y., Rowley J.A., San-
tiago N.M., Brunelle A.N., Berkman C.E. (2004) Probing for a
hydrophobic a binding register in prostate-specific membrane
antigen with phenylalkylphosphonamidates. Bioorg Med Chem;
12:4969–4979.
18. Banerjee S.R., Foss C.A., Castanares M., Mease R.C., Byun Y.,
Fox J.J., Hilton J., Lupold S.E., Kozikowski A.P., Pomper M.G.
(2008) Synthesis and evaluation of technetium-99m- and rhe-
nium-labeled inhibitors of the prostate-specific membrane anti-
gen (PSMA). J Med Chem;51:4504–4517.
19. Mease R.C., Dusich C.L., Foss C.A., Ravert H.T., Dannals R.F.,
Seidel J., Prideaux A., Fox J.J., Sgouros G., Kozikowski A.P.,
Pomper M.G. (2008) N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-
[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe
for prostate cancer. Clin Cancer Res;14:3036–3043.
20. Lapi S.E., Wahnishe H., Pham D., Wu L.Y., Nedrow-Byers J.R.,
Liu T., Vejdani K., VanBrocklin H.F., Berkman C.E., Jones E.F.
(2009) Assessment of an 18F-labeled phosphoramidate peptido-
mimetic as a new prostate-specific membrane antigen-targeted
imaging agent for prostate cancer. J Nucl Med;50:2042–2048.
21. Dijkgraaf I., Boerman O.C. (2009) Radionuclide imaging of tumor
angiogenesis. Cancer Biother Radiopharm;24:637–647.
22. Barinka C., Rovenska M., Mlcochova P., Hlouchova K., Plechanov-
ova A., Majer P., Tsukamoto T., Slusher B.S., Konvalinka J.,
Lubkowski J. (2007) Structural insight into the pharmacophore
35. Anderson M.O., Wu L.Y., Santiago N.M., Moser J.M., Rowley J.A.,
Bolstad E.S., Berkman C.E. (2007) Substrate specificity of prostate-
specific membrane antigen. Bioorg Med Chem;15:6678–6686.
36. Zhou A., Rayabarapu D., Hanson P.R. (2008) Click, Click, Cyclize:
A
DOS Approach to Sultams Utilizing Vinyl Sulfonamide
Linchpins. Organic Letters;11:531–534.
37. Mesters J.R., Barinka C., Li W., Tsukamoto T., Majer P., Slusher
B.S., Konvalinka J., Hilgenfeld R. (2006) Structure of glutamate
carboxypeptidase II, a drug target in neuronal damage and pros-
tate cancer. EMBO J;25:1375–1384.
pocket of human glutamate carboxypeptidase.
Chem;50:3267–3273.
23. Mesters J.R., Henning K., Hilgenfeld R. (2007) Human glutamate
carboxypeptidase II inhibition: structures of GCPII in complex
with two potent inhibitors, quisqualate and 2-PMPA. Acta Crys-
tallogr D Biol Crystallogr;63:508–513.
J
Med
38. Wang H., Byun Y., Barinka C., Pullambhatla M., Bhang H.E., Fox
J.J., Lubkowski J., Mease R.C., Pomper M.G. (2010) Bioisoster-
ism of urea-based GCPII inhibitors: Synthesis and structure-
activity relationship studies. Bioorg Med Chem Lett;20:392–397.
Supporting Information
24. Barinka C., Byun Y., Dusich C.L., Banerjee S.R., Chen Y., Castan-
ares M., Kozikowski A.P., Mease R.C., Pomper M.G., Lubkowski
J. (2008) Interactions between human glutamate carboxypepti-
dase II and urea-based inhibitors: structural characterization. J
Med Chem;51:7737–7743.
25. Peng X.Q., Li J., Gardner E.L., Ashby C.R. Jr, Thomas A.,
Wozniak K., Slusher B.S., Xi Z.X. (2010) Oral administration of
the NAALADase inhibitor GPI-5693 attenuates cocaine-induced
reinstatement of drug-seeking behavior in rats. Eur J Pharma-
col;627:156–161.
Additional Supporting Information may be found in the online ver-
sion of this article:
Figure S1. Three-dimensional pose of ethyl sulfonamide inhibitor
2d (11.6 lM) docked into the active site of GCP2 (PDB = 2C6C).
Figure S2. Three-dimensional pose of propyl sulfonamide inhibitor
2g (5 lM, most potent in this series) docked into the active site of
GCP2 (PDB = 2C6C).
26. Bonnac L., Innocenti A., Winum J.-Y., Casini A., Montero J.-L.,
Scozzafava A., Barragan V., Supuran C.T. (2004) Carbonic anhy-
drase inhibitors. Sulfonamide diuretics revisited–old leads for
new applications? J Enzyme Inhib Med Chem;pp. 275–278.
27. Temperini C., Cecchi A., Scozzafava A., Supuran C.T. (2008) Car-
bonic anhydrase inhibitors. Sulfonamide diuretics revisited–old
leads for new applications? Org Biomol Chem;6:2499–2506.
28. Supuran C.T. (2008) Carbonic anhydrases: novel therapeutic
applications for inhibitors and activators. Nat Rev Drug Dis-
cov;7:168–181.
29. Scozzafava A., Owa T., Mastrolorenzo A., Supuran C.T. (2003)
Anticancer and antiviral sulfonamides. Curr Med Chem;10:925–
953.
30. Supuran C.T., Casini A., Scozzafava A. (2003) Protease inhibitors
of the sulfonamide type: anticancer, antiinflammatory, and anti-
viral agents. Med Res Rev;23:535–558.
Figure S3. Three-dimensional pose of butyl sulfonamide inhibitor
2h docked into the active site of GCP2 (PDB = 2C6C). The n-butyl
group forces the glutamate a-carboxyl group away from the cata-
lytic zinc atoms, producing a significant drop in potency (55 lM).
Table S1. Characterization of sulfonamide products by 1H NMR
and MS (low res or high res).
Table S2. Characterization of representative sulfonamide products
(2) and protected intermediates (4, 5) by 13C NMR.
Please note: Wiley-Blackwell is not responsible for the content or
functionality of any supporting materials supplied by the authors.
Any queries (other than missing material) should be directed to the
corresponding author for the article.
Chem Biol Drug Des 2011; 77: 241–247
247